The Future of Biopharma: What Does the Industry Want & Need?
ISPE
What Does the Industry Want and Need?
Eric S. Langer, President and Managing Partner, BioPlan Associates, Inc., shared these most-needed cell and gene therapy manufacturing improvement, systems, platforms, and infrastructure from his company’s research1
at the 2019 ISPE Biopharmaceutical Manufacturing Conference (as indicated by the percentages of survey respondents who chose these options):
FDA Forges Ahead to Support Cell and Gene Therapy
The FDA is working to streamline the review and safety reporting requirements for gene therapy protocols.2
NIH’s Recombinant DNA Advisory Committee (RAC) will transition to become the Novel and Exceptional Technology and Research Advisory Committee (NExTRAC), focusing on evaluating new biotechnologies and emerging applications.
ISPE delivers technical and operational solutions to support across the global pharmaceutical and biopharmaceutical industry in the manufacture of quality medicines for patients.
The new year is here and, with that, another International Women’s Day approaches! This incredibly important global movement, which takes place every 8 March, celebrates women’s achievements, raises awareness about discrimination, and advocates for accelerated equality and gender parity. ISPE’s Women in Pharma® community strives to accomplish all these goals through regional and international...
The 2023 ISPE Pharma 4.0™ and Annex 1 Conference was held in Barcelona, Spain, 11–12 December. Topics discussed included transforming operations, quality, and maintenance with Pharma 4.0™ principles...
Although he didn’t know it at the time, Nathan Temple’s service as a naval officer on the USS Asheville in Hawaii prepared him perfectly for a career in pharmaceutical engineering. “You learn so much, so quickly, on a submarine.”